DLHW Tetrapeptide Neuroprotective Compound
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases lack effective neuroprotective and neurotrophic agents that can improve neuronal viability and memory functions, and there is a need for novel compounds that can target specific sites in the body for enhanced therapeutic efficacy.
Innovation Solution
A neuroprotective compound with the amino acid sequence DLHW, which can be administered alone or conjugated with proteins or other molecules, exhibits neuroprotective and neurotrophic properties by affecting neuronal cell viability and stimulating growth, and can be formulated with other active components for enhanced therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional neuroprotective agents are used, then some neuroprotective effect is achieved, but they lack sufficient efficacy in improving neuronal viability and memory functions
Solution Approach 1:
The patent segments the complex problem of neuroprotection into a simple tetrapeptide structure (DLHW). By dividing the therapeutic function into a small, specific amino acid sequence, the invention achieves high efficacy in improving neuronal viability without the complexity of larger molecules or combination therapies.
Solution Approach 2:
The invention changes the critical parameter of peptide sequence to DLHW, which specifically activates neuroprotective pathways. This parameter change transforms an ineffective or weakly effective conventional approach into a highly effective treatment that significantly improves neuronal viability and memory functions.
2Reliability
If neuroprotective compounds are administered alone, then the compound structure is simple, but therapeutic efficacy is limited; if conjugated with proteins or other molecules, then therapeutic efficacy is enhanced, but the compound structure becomes more complex
Solution Approach 1:
The DLHW tetrapeptide serves multiple functions: it can be administered alone for basic neuroprotection, or conjugated with proteins, antibodies, or other molecules for targeted delivery and enhanced efficacy. This multi-functionality allows the same core compound to adapt to different therapeutic needs without requiring entirely different molecules.
Solution Approach 2:
The DLHW tetrapeptide acts as an intermediary that can bridge simple administration with complex targeted therapy. When conjugated with proteins or antibodies, it serves as the active component that mediates the therapeutic effect, allowing the benefits of complex targeted delivery while maintaining a simple, well-defined active principle.
3Adaptability or versatility
If current treatments are used, then existing therapeutic options are available, but they lack effective neurotrophic agents that can stimulate neuronal growth and improve memory functions
Solution Approach 1:
Instead of trying to modify existing large neuroprotective molecules to add neurotrophic activity, the invention inverts the approach by using a small tetrapeptide that inherently possesses both neuroprotective and neurotrophic properties. This inverted strategy of starting small and building functionality proves more effective than starting large and trying to add functions.
Data Source
AI summary
The present invention relates to a neuroprotective compound consisting of the amino acid sequence DLHW.